Natera (NTRA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $404.79, +2.54% vs the prior close of $394.75.
- Volume 1.21M shares, 0.8x its 50-day average.
- New SEC filings: 144 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
NTRA rises 2.5% to $404.79. Closed at $404.79, +2.54% vs the prior close of $394.75. Day range $384.23–$408.82, opened at $389.88.
NTRA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — NTRA rises 2.5% to $404.79
- Closed at $404.79, +2.54% vs the prior close of $394.75. Day range $384.23–$408.82, opened at $389.88.
- Volume was 1.21M shares, 0.8x its 50-day average of 1.56M.
- Price is +13.9% vs its 50-day average ($355.52) and +57.7% vs its 200-day average ($256.68).
- 52-week range $172.82–$437.41; today's close sits at 88% of that range, 7.5% below the 52-week high.
Oct 14, 2026 — NTRA ends flat (-0.2%) to $394.75, 3 down days in a row
- Closed at $394.75, -0.23% vs the prior close of $395.65. Day range $391.28–$405.11, opened at $394.40.
- Volume was 1.05M shares, 0.7x its 50-day average of 1.58M.
- Price is +11.9% vs its 50-day average ($352.92) and +54.3% vs its 200-day average ($255.81).
- 52-week range $170.82–$437.41; today's close sits at 84% of that range, 9.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — NTRA dips 0.5% to $395.65
- Closed at $395.65, -0.53% vs the prior close of $397.77. Day range $383.01–$397.53, opened at $396.98.
- Volume was 1.13M shares, 0.7x its 50-day average of 1.58M.
- Price is +12.9% vs its 50-day average ($350.53) and +55.2% vs its 200-day average ($255.01).
- 52-week range $169.08–$437.41; today's close sits at 84% of that range, 9.5% below the 52-week high.
Oct 12, 2026 — NTRA dips 0.7% to $397.77
- Closed at $397.77, -0.73% vs the prior close of $400.71. Day range $387.74–$402.40, opened at $401.96.
- Volume was 935.10K shares, 0.6x its 50-day average of 1.59M — lighter than usual.
- Price is +14.3% vs its 50-day average ($348.02) and +56.5% vs its 200-day average ($254.20).
- 52-week range $167.99–$437.41; today's close sits at 85% of that range, 9.1% below the 52-week high.
Oct 9, 2026 — NTRA rises 2.5% to $400.71
- Closed at $400.71, +2.54% vs the prior close of $390.79. Day range $391.51–$407.06, opened at $392.90.
- Volume was 1.01M shares, 0.6x its 50-day average of 1.59M.
- Price is +16.0% vs its 50-day average ($345.42) and +58.1% vs its 200-day average ($253.39).
- 52-week range $167.99–$437.41; today's close sits at 86% of that range, 8.4% below the 52-week high.
Oct 8, 2026 — NTRA dips 1.2% to $390.79, 3 down days in a row
- Closed at $390.79, -1.21% vs the prior close of $395.56. Day range $380.39–$392.95, opened at $387.59.
- Volume was 2.44M shares, 1.6x its 50-day average of 1.56M.
- Price is +14.0% vs its 50-day average ($342.80) and +54.7% vs its 200-day average ($252.57).
- 52-week range $167.99–$437.41; today's close sits at 83% of that range, 10.7% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — NTRA dips 1.3% to $395.56 on 1.8x normal volume
- Closed at $395.56, -1.27% vs the prior close of $400.65. Day range $383.45–$401.09, opened at $393.02.
- Volume was 2.82M shares, 1.8x its 50-day average of 1.52M — unusually heavy trading.
- Price is +16.3% vs its 50-day average ($340.06) and +57.1% vs its 200-day average ($251.77).
- 52-week range $167.33–$437.41; today's close sits at 85% of that range, 9.6% below the 52-week high.
Oct 6, 2026 — NTRA slides 5.9% to $400.65
- Closed at $400.65, -5.87% vs the prior close of $425.64. Day range $394.77–$437.41, opened at $429.01.
- Volume was 2.50M shares, 1.7x its 50-day average of 1.49M.
- Price is +18.8% vs its 50-day average ($337.20) and +59.7% vs its 200-day average ($250.92).
- 52-week range $167.21–$437.41; today's close sits at 86% of that range, 8.4% below the 52-week high.
Oct 5, 2026 — NTRA jumps 3.7% to $425.64, a 52-week high
- Closed at $425.64, +3.73% vs the prior close of $410.35. Day range $405.24–$427.18, opened at $410.32.
- Volume was 2.02M shares, 1.4x its 50-day average of 1.47M.
- Price is +27.3% vs its 50-day average ($334.34) and +70.2% vs its 200-day average ($250.04).
- 52-week range $160.59–$427.47; today's close sits at 99% of that range, 0.4% below the 52-week high.
Oct 2, 2026 — NTRA rises 0.5% to $410.35
- Closed at $410.35, +0.46% vs the prior close of $408.47. Day range $401.00–$413.36, opened at $409.40.
- Volume was 2.16M shares, 1.5x its 50-day average of 1.44M.
- Price is +23.9% vs its 50-day average ($331.07) and +64.8% vs its 200-day average ($249.05).
- 52-week range $157.43–$427.47; today's close sits at 94% of that range, 4.0% below the 52-week high.
NTRA latest news & SEC filings
Every SEC filing by or about NTRA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 9, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Rabinowitz Matthew gifted 6,000 shares on Oct 7, 2026; now holds 2,119,394
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Chapman Steven Leonard sold 1,273 shares at $413.31 (≈$526.14K) on Oct 1, 2026; now holds 96,926
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Moshkevich Solomon sold 200 shares at $411.62 (≈$82.32K) on Oct 1, 2026; now holds 109,714
- Moshkevich Solomon sold 954 shares at $413.11 (≈$394.10K) on Oct 1, 2026; now holds 108,760
- Moshkevich Solomon sold 1,846 shares at $415.07 (≈$766.22K) on Oct 1, 2026; now holds 106,914
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 1, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · S-8 — Registration of shares for employee stock plans (S-8)
Registration of shares for employee stock plans (S-8)
Aug 7, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $752.75M (prior year $546.60M) (+37.7% vs Jun 30, 2025)
- Net income: -$66.97M (prior year -$100.94M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.47 (prior year -$0.74) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade NTRA
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.68% (largest 5.9%).
- Liquidity: about 1.86M shares (≈$752.81M) trade per day on average.
- 52-week position: $404.79 vs a range of $172.82–$437.41 (88% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jonathan Sheena sold 390 shares on Sep 23, 2026.
- Latest filings: 10-Q Aug 7, 2026; 8-K Aug 6, 2026; 8-K Jul 6, 2026.
- Share count: 144.14M shares outstanding (Jul 31, 2026), +5.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Services-Medical Laboratories.
NTRA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 389.88 | 408.82 | 384.23 | 404.79 | 1.21M |
| Oct 14, 2026 | 394.40 | 405.11 | 391.28 | 394.75 | 1.05M |
| Oct 13, 2026 | 396.98 | 397.53 | 383.01 | 395.65 | 1.13M |
| Oct 12, 2026 | 401.96 | 402.40 | 387.74 | 397.77 | 935.10K |
| Oct 9, 2026 | 392.90 | 407.06 | 391.51 | 400.71 | 1.01M |
| Oct 8, 2026 | 387.59 | 392.95 | 380.39 | 390.79 | 2.44M |
| Oct 7, 2026 | 393.02 | 401.09 | 383.45 | 395.56 | 2.82M |
| Oct 6, 2026 | 429.01 | 437.41 | 394.77 | 400.65 | 2.50M |
| Oct 5, 2026 | 410.32 | 427.18 | 405.24 | 425.64 | 2.02M |
| Oct 2, 2026 | 409.40 | 413.36 | 401.00 | 410.35 | 2.16M |
| Oct 1, 2026 | 413.31 | 423.43 | 407.37 | 408.47 | 1.86M |
| Sep 30, 2026 | 416.02 | 427.47 | 413.29 | 413.31 | 1.85M |
| Sep 29, 2026 | 413.69 | 421.64 | 409.25 | 414.52 | 2.06M |
| Sep 28, 2026 | 409.02 | 417.38 | 406.30 | 411.77 | 1.64M |
| Sep 25, 2026 | 410.00 | 415.75 | 407.48 | 412.56 | 1.61M |
| Sep 24, 2026 | 390.52 | 412.92 | 388.46 | 408.79 | 1.96M |
| Sep 23, 2026 | 386.94 | 394.86 | 384.96 | 390.79 | 1.69M |
| Sep 22, 2026 | 368.26 | 391.93 | 365.20 | 390.90 | 1.55M |
| Sep 21, 2026 | 371.92 | 373.07 | 363.96 | 370.64 | 1.98M |
| Sep 18, 2026 | 365.78 | 369.69 | 358.90 | 369.39 | 3.72M |
About Natera
Natera (NTRA) is listed on the Nasdaq and classified by the SEC under “Services-Medical Laboratories”. Its business address is in AUSTIN, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1604821.
NTRA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Roelof Botha | Director | Jun 30, 2026 |
| Roy D. Baynes | Director | Jun 30, 2026 |
| Monica Bertagnolli | Director | Jun 30, 2026 |
| Rowan E Chapman | Director | Jul 17, 2026 |
| Steven Leonard Chapman | CEO AND PRESIDENT | Sep 3, 2026 |
| Thomas J. Jr. Lynch | Director | Jun 30, 2026 |
| Gail Boxer Marcus | Director | Jun 30, 2026 |
| Herm Rosenman | Director | Jun 30, 2026 |
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sep 16, 2026 |
| Eric H Rubin | Director | Jun 30, 2026 |
| Jonathan Sheena | CO-FOUNDER | Sep 25, 2026 |
| Brinkley Ruth Williams | Director | Apr 28, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | Aug 5, 2026 |
| Steven Leonard Chapman | CEO AND PRESIDENT | Sep 3, 2026 |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | Aug 28, 2026 |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Sep 18, 2026 |
| Daniel Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | Aug 5, 2026 |
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN | Sep 16, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 23, 2026 | Jonathan Sheena | Sale | 390 | $385.29 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 2,300 | $386.64 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 2,846 | $387.74 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 1,341 | $388.76 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 1,935 | $389.71 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 220 | $390.53 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 400 | $385.10 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 2,175 | $386.71 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 110 | $390.42 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 2,320 | $389.69 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 2,734 | $387.65 |
| Sep 23, 2026 | Jonathan Sheena | Sale | 1,293 | $388.71 |
| Sep 16, 2026 | Jonathan Sheena | Sale | 200 | $348.03 |
| Sep 16, 2026 | Jonathan Sheena | Sale | 200 | $356.87 |
| Sep 16, 2026 | Jonathan Sheena | Sale | 800 | $355.95 |
NTRA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.31B | $-208.16M | -1.52 | $215.30M |
| Dec 31, 2024 | $1.70B | $-190.43M | -1.53 | $135.66M |
| Dec 31, 2023 | $1.08B | $-434.80M | -3.78 | $-246.96M |
| Dec 31, 2022 | $820.22M | $-547.80M | -5.57 | $-431.50M |
| Dec 31, 2021 | $625.49M | $-471.72M | -5.21 | $-335.24M |
Latest balance sheet: total assets $2.66B, total liabilities $836.00M, cash $466.00M (as of Jun 30, 2026).
NTRA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $265.38 |
| May 7, 2026 | 8-K Item 2.02 (results) | $219.82 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $216.10 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $235.45 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $198.48 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $141.08 |
| May 8, 2025 | 8-K Item 2.02 (results) | $162.57 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $156.61 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $169.30 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $135.12 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Medical Laboratories
Quest Diagnostics (DGX)Guardant Health (GH)Labcorp (LH)Celcuity (CELC)Caris Life Sciences (CAI)Grail (GRAL)CareDx (CDNA)Fortrea (FTRE)Veracyte (VCYT)BillionToOne (BLLN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on NTRA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.